Technical Analysis for CNTB - Connect Biopharma Holdings Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bullish Engulfing | Bullish | -5.70% | |
| Lower Bollinger Band Walk | Weakness | -5.70% | |
| Outside Day | Range Expansion | -5.70% | |
| Wide Bands | Range Expansion | -5.70% | |
| Gapped Down | Weakness | -5.70% | |
| Lower Bollinger Band Touch | Weakness | -5.70% | |
| Oversold Stochastic | Weakness | -5.70% | |
| Lower Bollinger Band Walk | Weakness | 1.55% | |
| Wide Bands | Range Expansion | 1.55% | |
| Lower Bollinger Band Touch | Weakness | 1.55% |
| Alert | Time |
|---|---|
| Gap Down Closed | about 2 hours ago |
| 60 Minute Opening Range Breakout | about 2 hours ago |
| 10 DMA Resistance | about 2 hours ago |
| Gap Down Partially Closed | about 3 hours ago |
| Gapped Down (Partial) | about 4 hours ago |
Get a Trading Assistant
- Earnings date: 04/15/2024
Connect Biopharma Holdings Limited Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunology Immune System Immunotherapy Inflammation Asthma Atopic Dermatitis Chronic Rhinosinusitis Human Physiology Skin Inflammation Animal Physiology Interleukins Nasal Polyps
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.66 |
| 52 Week Low | 0.6777 |
| Average Volume | 24,886 |
| 200-Day Moving Average | 1.36 |
| 50-Day Moving Average | 1.22 |
| 20-Day Moving Average | 1.12 |
| 10-Day Moving Average | 1.05 |
| Average True Range | 0.10 |
| RSI (14) | 43.50 |
| ADX | 14.55 |
| +DI | 16.86 |
| -DI | 23.56 |
| Chandelier Exit (Long, 3 ATRs) | 1.09 |
| Chandelier Exit (Short, 3 ATRs) | 1.22 |
| Upper Bollinger Bands | 1.30 |
| Lower Bollinger Band | 0.95 |
| Percent B (%b) | 0.29 |
| BandWidth | 31.05 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.05 |
| MACD Histogram | -0.0085 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.26 | ||||
| Resistance 3 (R3) | 1.24 | 1.14 | 1.22 | ||
| Resistance 2 (R2) | 1.14 | 1.09 | 1.15 | 1.21 | |
| Resistance 1 (R1) | 1.10 | 1.06 | 1.12 | 1.12 | 1.20 |
| Pivot Point | 1.00 | 1.00 | 1.02 | 1.02 | 1.00 |
| Support 1 (S1) | 0.96 | 0.95 | 0.98 | 0.98 | 0.90 |
| Support 2 (S2) | 0.86 | 0.92 | 0.88 | 0.89 | |
| Support 3 (S3) | 0.82 | 0.86 | 0.88 | ||
| Support 4 (S4) | 0.84 |
